SMi's Controlled Release conference to feature keynote presentations from the MHRA and US FDA, along with case studies from an array of global pharmaceutical companies

Share Article

SMi's 13th annual Controlled Release conference, taking place on 18th - 19th April 2016 in London, will feature an array of case studies and project updates from major global pharmaceutical companies and leading regulatory bodies.

SMi's 13th annual Controlled Release conference

SMi's Controlled Release conference is the only industry event which will feature MHRA and US FDA representation to clarify your regulatory uncertainties, and provide you with updates from your industry colleagues on the latest innovations to accelerate commercialisation, as well as on developments in the regulatory landscape to ensure strict compliance. The two-day programme is packed with unmissable case studies from global pharma companies including GlaxoSmithKline, Ipsen, Novo Nordisk, MedImmune, AstraZeneca, Lundbeck, Merck, UCB Pharma, Critical Pharmaceuticals, Kashiv Pharma and Diurnal:

  •     The importance of QbD

GSK examines how Quality by Design (QbD) can aid formulation and controlled release delivery
Novo Nordisk demonstrates application of QbD during spray drying scale-up

  •     Innovations in Controlled Release

MedImmune talks about controlling peptide stability to unlock therapeutic potential
AstraZeneca presents nanomedicine design for controlled release

  •     Product Design

Parenteral controlled release: Revival for increased adherence – case study by Merck
Lundbeck showcases how to formulate poorly soluble drugs

  •     New platforms in Controlled Release delivery

CriticalMix platform technology: A novel platform technology for sustained delivery of small and large APIs by Critical Pharmaceuticals
Diurnal on optimising drug delivery systems to mimic the human circadian rhythm

Don't forget to extend your stay to join the two interactive post-conference workshops taking place on Wednesday 20th April 2016:

Workshop A: QbD/PAT Driven Controlled Release Design and Development
Hosted by by Daniela Stranges, Senior Scientist, Quality by Design Integration, GlaxoSmithKline and Jerome Mantanus, Senior Scientist QbD/PAT Drug Product Formulation, UCB Pharma
Enhance understanding on the adoption of core principles of Quality by Design (QbD) for controlled release development and manufacturing. This workshop defines how QbD tools (DoEs, PAT) can be applied to support formulation and process development.

Workshop B: Exploring Controlled Release Drug Delivery Methods
Hosted by Rene Holm, Senior Director, Lundbeck; Clive Wilson, Professor of Pharmaceutics, University of Strathclyde; Ijeoma Uchegbu, Scientific Secretary CRS, Chair in Pharmaceutical Nanoscience, University of London and CEO, Nanometrics
This workshop will explore drug delivery technologies that can be utilised in controlled release drug delivery and will consider some of the newer concepts in the drug delivery world including nanotechnology.

To view the full speaker line-up and conference programme, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Teri Arri
SMi Group
+44 2078276162
Email >
since: 10/2011
Follow >
Visit website